Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Cortes J, Lipton JH, Rea D, Digumarti R, Chuah C, Nanda N, Benichou AC, Craig AR, Michallet M, Nicolini FE, Kantarjian H; Omacetaxine 202 Study Group. Cortes J, et al. Among authors: benichou ac. Blood. 2012 Sep 27;120(13):2573-80. doi: 10.1182/blood-2012-03-415307. Epub 2012 Aug 15. Blood. 2012. PMID: 22896000 Free PMC article. Clinical Trial.
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib.
Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard L, Craig A, Nanda N, Benichou AC, Leonoudakis J, Khoury HJ, Hochhaus A, Baccarani M, Kantarjian HM. Cortes JE, et al. Among authors: benichou ac. Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):584-91. doi: 10.1016/j.clml.2013.03.020. Epub 2013 Jun 17. Clin Lymphoma Myeloma Leuk. 2013. PMID: 23787123 Free PMC article. Clinical Trial.
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors.
Nemunaitis J, Mita A, Stephenson J, Mita MM, Sarantopoulos J, Padmanabhan-Iyer S, Nanda N, Gleich L, Benichou AC, Craig A. Nemunaitis J, et al. Among authors: benichou ac. Cancer Chemother Pharmacol. 2013 Jan;71(1):35-41. doi: 10.1007/s00280-012-1963-2. Epub 2012 Oct 4. Cancer Chemother Pharmacol. 2013. PMID: 23053254 Free PMC article. Clinical Trial.
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.
Nicolini FE, Khoury HJ, Akard L, Rea D, Kantarjian H, Baccarani M, Leonoudakis J, Craig A, Benichou AC, Cortes J. Nicolini FE, et al. Among authors: benichou ac. Haematologica. 2013 Jul;98(7):e78-9. doi: 10.3324/haematol.2012.083006. Epub 2013 Jun 10. Haematologica. 2013. PMID: 23753022 Free PMC article. No abstract available.
First-in-human trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of STR-324, a dual enkephalinase inhibitor for pain management.
Moss LM, Berends CL, van Brummelen EMJ, Kamerling IMC, Klaassen ES, Bergmann K, Ville V, Juarez-Perez V, Benichou AC, Groeneveld GJ. Moss LM, et al. Among authors: benichou ac. Br J Clin Pharmacol. 2022 Jan;88(1):103-114. doi: 10.1111/bcp.14931. Epub 2021 Jul 16. Br J Clin Pharmacol. 2022. PMID: 34046921 Free PMC article. Clinical Trial.
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Cortes J, Digumarti R, Parikh PM, Wetzler M, Lipton JH, Hochhaus A, Craig AR, Benichou AC, Nicolini FE, Kantarjian HM; Omacetaxine 203 Study Group. Cortes J, et al. Among authors: benichou ac. Am J Hematol. 2013 May;88(5):350-4. doi: 10.1002/ajh.23408. Epub 2013 Mar 7. Am J Hematol. 2013. PMID: 23468307 Free PMC article. Clinical Trial.